AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 
Italy Fines Apple €98.6 Million Over App Store Dominance 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
NEW YORK, Feb. 03, 2016 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Imprivata, Inc. (“Imprivata”) (NYSE:IMPR) between July 30, 2015 and November 2, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of Massachusetts. If you purchased or otherwise acquired Imprivata securities between July 30, 2015 and November 2, 2015, your rights may be affected by this action. To get more information go to: http://zlk.9nl.com/imprivata.
The complaint alleges that during the Class Period, defendants made materially false and misleading statements and/or omitted material information concerning demand for the Company’s IT security offerings and its sales trends, thereby inflating the price of Imprivata stock. The complaint further alleges that certain Imprivata executives and insiders took advantage of the inflation by selling more than $72 million worth of personally-held Imprivata stock during this timeperiod.
If you suffered a loss in Imprivata you have until April 4, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/imprivata.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Eduard Korsinsky, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
